Developer docs
API playgroundTry for free, no card

Search company profiles

MitrAssist

Full company profile

uuid00024v5

Namestring
MitrAssist
Websiteurl
mitrassist.com
Company typeenum
Private
Founded yearint
2009
Short descriptiontext

MitrAssist is an Israel-based medtech startup developing transcatheter mitral valve technology for minimally invasive treatment of mitral regurgitation, serving hospitals and cardiac care centers through enterprise sales of its Mitraclip-based TEER platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMisgav Dov, Israel
HQ citystring
Misgav Dov
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
transcatheter mitral valve, mitral regurgitation treatment, minimally invasive cardiac devices, structural heart intervention, cardiac medical devices
Industry3 codes
1Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
CodeHLAHAFALPrimaryYes
2Interventional Cardiology (PCI/Structural Heart)
CodeHLAKABABPrimaryNo
3Surgical, Perioperative & ERAS Pathway Tools
CodeHLACAGAJPrimaryNo
NAICS code1 code
  • Freestanding Ambulatory Surgical and Emergency Centers621493
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Cardiac Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Revenue generated from transcatheter mitral valve devices sold to hospitals and cardiac care centers for minimally invasive mitral valve repair procedures

mdpi.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MitrAssist develops transcatheter mitral valve medical devices that enable minimally invasive treatment of mitral regurgitation. The company's technology targets patients who are high-risk candidates for traditional open-heart surgery and is supported by clinical research demonstrating the predictive utility of the EROA/LVEDV ratio for patient outcomes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • EROA/LVEDV ratio demonstrated moderate predictive value (AUC 0.74) for one-year symptom worsening (heart failure hospitalizations or death)
Product and service1 record
1Transcatheter Mitral Valve Device
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Peers10 records
1HighLife Medical
TypeEmerging player
Description

HighLife Medical is developing a transcatheter mitral valve replacement system, pursuing the same minimally invasive mitral regurgitation therapy market as MitrAssist.

2Edwards Lifesciences
TypeBroad incumbent
Description

Edwards offers the PASCAL transcatheter mitral repair system and is a leader in structural heart, making it a direct competitor in transcatheter mitral valve therapy with deep clinical and commercial resources.

3NeoChord
TypeEmerging player
Description

NeoChord develops transcatheter chordal repair technology for degenerative mitral regurgitation, offering a competing minimally invasive approach for the same patient population MitrAssist targets.

4Medtronic
TypeBroad incumbent
Description

Medtronic is developing the Intrepid TMVR system and has a broad structural heart portfolio, positioning it as a major competing incumbent in transcatheter mitral valve technologies.

5Cardiovalve
TypeEmerging player
Description

Cardiovalve is developing a transcatheter mitral and tricuspid valve replacement system, positioning it as a direct emerging competitor pursuing similar minimally invasive mitral regurgitation treatment approaches.

6Cephea Valve Technologies
TypeEmerging player
Description

Cephea is developing a transcatheter mitral valve replacement technology, making it a direct emerging peer in the structural mitral valve space.

7Boston Scientific
TypeBroad incumbent
Description

Boston Scientific has invested in mitral and tricuspid transcatheter repair technologies (e.g., through acquisitions and partnerships), making it a broad incumbent in the structural heart space that overlaps with MitrAssist's focus.

84C Medical Technologies
TypeEmerging player
Description

4C Medical is developing the AltaValve system for transcatheter mitral regurgitation treatment, making it a comparable emerging medtech focused on the same mitral regurgitation indication.

9Abbott
TypeBroad incumbent
Description

Abbott markets MitraClip, the dominant transcatheter edge-to-edge mitral repair device with FDA approval, established reimbursement, and broad hospital adoption — the primary incumbent MitrAssist must displace in the TEER space.

10LivaNova
TypeBroad incumbent
Description

LivaNova has historically been involved in mitral valve repair products (including the Memo 3D annuloplasty ring and prior Caisson TMVR program), positioning it as an incumbent with adjacent structural heart capabilities.

Market position
Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MitrAssist

Cardiac Medical Devicesmitrassist.com

MitrAssist is an Israel-based medtech startup developing transcatheter mitral valve technology for minimally invasive treatment of mitral regurgitation, serving hospitals and cardiac care centers through enterprise sales of its Mitraclip-based TEER platform.

MitrAssist firmographics

Firmographics
Name
MitrAssist
Website
https://mitrassist.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
MitrAssist is an Israel-based medtech startup developing transcatheter mitral valve technology for minimally invasive treatment of mitral regurgitation, serving hospitals and cardiac care centers through enterprise sales of its Mitraclip-based TEER platform.
Ownership category
akta.pro rank

MitrAssist industry classification

Industry
Product category
Cardiac Medical Devices
NAICS
Freestanding Ambulatory Surgical and Emergency Centers (621493)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro primary industry
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
akta.pro secondary industries
Interventional Cardiology (PCI/Structural Heart) (HLAKABAB), Surgical, Perioperative & ERAS Pathway Tools (HLACAGAJ)

Keywords

  • Transcatheter mitral valve
  • Mitral regurgitation treatment
  • Minimally invasive cardiac devices
  • Structural heart intervention
  • Cardiac medical devices

Where MitrAssist is headquartered

Location

Headquarters

HQ city
Misgav Dov
HQ country
Israel
HQ region
Middle East

Markets served

MitrAssist business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Revenue generated from transcatheter mitral valve devices sold to hospitals and cardiac care centers for minimally invasive mitral valve repair procedures

Go-to-market motion1 record

Distribution channels1 record

MitrAssist product offering

Product offering

Core offering

MitrAssist develops transcatheter mitral valve medical devices that enable minimally invasive treatment of mitral regurgitation. The company's technology targets patients who are high-risk candidates for traditional open-heart surgery and is supported by clinical research demonstrating the predictive utility of the EROA/LVEDV ratio for patient outcomes.

Differentiator

Problem solved

Functional benefit

Products and services

  • Transcatheter Mitral Valve Device

Quantifiable outcome

  • EROA/LVEDV ratio demonstrated moderate predictive value (AUC 0.74) for one-year symptom worsening (heart failure hospitalizations or death)

Companies that use MitrAssist

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

MitrAssist technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

MitrAssist partnerships and signals

Strategic signal

Scale indicators3 records

MitrAssist competitors and assessment

Company assessment

Emerging players

  • HighLife Medical: HighLife Medical is developing a transcatheter mitral valve replacement system, pursuing the same minimally invasive mitral regurgitation therapy market as MitrAssist.
  • NeoChord: NeoChord develops transcatheter chordal repair technology for degenerative mitral regurgitation, offering a competing minimally invasive approach for the same patient population MitrAssist targets.
  • Cardiovalve: Cardiovalve is developing a transcatheter mitral and tricuspid valve replacement system, positioning it as a direct emerging competitor pursuing similar minimally invasive mitral regurgitation treatment approaches.
  • Cephea Valve Technologies: Cephea is developing a transcatheter mitral valve replacement technology, making it a direct emerging peer in the structural mitral valve space.
  • 4C Medical Technologies: 4C Medical is developing the AltaValve system for transcatheter mitral regurgitation treatment, making it a comparable emerging medtech focused on the same mitral regurgitation indication.

Broad incumbents

  • Edwards Lifesciences: Edwards offers the PASCAL transcatheter mitral repair system and is a leader in structural heart, making it a direct competitor in transcatheter mitral valve therapy with deep clinical and commercial resources.
  • Medtronic: Medtronic is developing the Intrepid TMVR system and has a broad structural heart portfolio, positioning it as a major competing incumbent in transcatheter mitral valve technologies.
  • Boston Scientific: Boston Scientific has invested in mitral and tricuspid transcatheter repair technologies (e.g., through acquisitions and partnerships), making it a broad incumbent in the structural heart space that overlaps with MitrAssist's focus.
  • Abbott: Abbott markets MitraClip, the dominant transcatheter edge-to-edge mitral repair device with FDA approval, established reimbursement, and broad hospital adoption — the primary incumbent MitrAssist must displace in the TEER space.
  • LivaNova: LivaNova has historically been involved in mitral valve repair products (including the Memo 3D annuloplasty ring and prior Caisson TMVR program), positioning it as an incumbent with adjacent structural heart capabilities.

Market position

Customer concentration

MitrAssist social profiles

Digital presence

MitrAssist financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MitrAssist leadership team

Management profile

Number of profiles

Profiles1 record

MitrAssist funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MitrAssist M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MitrAssist

What does MitrAssist do?

MitrAssist develops transcatheter mitral valve medical devices that enable minimally invasive treatment of mitral regurgitation. The company's technology targets patients who are high-risk candidates for traditional open-heart surgery and is supported by clinical research demonstrating the predictive utility of the EROA/LVEDV ratio for patient outcomes.

Is MitrAssist a public or private company?

MitrAssist is a private company. It is classified as venture growth investor backed and is currently operating.

When was MitrAssist founded?

MitrAssist was founded in 2009. It employs 1 to 10 people.

Where is MitrAssist based?

MitrAssist is headquartered in Misgav Dov, Israel, in the Middle East region.

How does MitrAssist make money?

One revenue line is on record: medical Device Sales.

Who are MitrAssist's main competitors?

Emerging players on record are HighLife Medical, NeoChord, Cardiovalve, Cephea Valve Technologies and 4C Medical Technologies. Broad incumbents are Edwards Lifesciences, Medtronic, Boston Scientific, Abbott and LivaNova.

Does MitrAssist have an API?

No public API is recorded for MitrAssist.

What industry is MitrAssist in?

MitrAssist's product category is Cardiac Medical Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAKABAB, Interventional Cardiology (PCI/Structural Heart). Its NAICS code is 621493 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals